(GNFT) Genfit - Ratings and Ratios

Genfit S.A. is a late-stage biopharmaceutical company specializing in the discovery and development of innovative drug candidates and diagnostic solutions for metabolic and liver-related diseases. The companys pipeline includes Elafibranor, currently in a pivotal Phase III clinical trial for the treatment of primary biliary cholangitis (PBC), a chronic liver disease characterized by progressive bile duct destruction. Additionally, Genfit is advancing NIS4 technology, a non-invasive diagnostic tool designed to identify nonalcoholic steatohepatitis (NASH) and fibrosis, addressing a significant unmet need in liver disease diagnosis.

The companys pipeline also includes VS-01, an investigational treatment for Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD), both rare genetic metabolic disorders. GNS561 is another key asset, currently in a Phase 1b/2a trial targeting cholangiocarcinoma (CCA), a aggressive form of bile duct cancer. VS-01-ACLF and Nitazoxanide (NTZ) are in Phase I development for acute-on-chronic liver failure (ACLF), while VS-02-HE is in preclinical stages for reducing hyperammonemia and stabilizing blood ammonia levels. The company also has CML-022 and SRT-015, an ASK1 inhibitor targeting cellular apoptosis, inflammation, and fibrosis.

Genfit has established strategic partnerships, including a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test for NASH. Additionally, the company has collaborated with Genoscience Pharma to develop and commercialize GNS561 for CCA. Incorporated in 1999 and headquartered in Loos, France, Genfit is positioned as a key player in the metabolic and liver disease space, leveraging its expertise in both therapeutic and diagnostic innovations. For more information, visit https://www.genfit.com.

3-Month Forecast: Based on the provided data, GNFT is expected to experience volatility as it transitions through its clinical pipeline milestones. The stock is trading below its SMA20 and SMA50, suggesting near-term weakness. However, with a forward P/E of 7.55 and a P/B ratio of 1.79, the stock may attract value investors. The low ATR of 0.12 indicates reduced price movement, while the average volume of 181,855 shares suggests moderate liquidity. The companys focus on high-unmet medical needs in liver and metabolic diseases positions it for potential long-term growth, though near-term price action may remain range-bound.